A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1

Authors
Category Primary study
ConferenceAIDS 2022 - the 24th International AIDS Conference
Year 2022
This article has no abstract
Epistemonikos ID: ea07087e1002939c22258c1b42f0bb5c292ee630
First added on: Jan 10, 2026